Renin–angiotensin system inhibitors and sodium-glucose cotransporter-2 inhibitors are recommended for patients with albuminuria, and statins are recommended for all patients with diabetes and CKD (29). This evidence concerns the gene SLC5A2 and chronic kidney disease.